Description
DAILYGLIM M1 FORTE Tablet is a fixed-dose combination oral antidiabetic for adults with type 2 diabetes who need stronger dual therapy for optimal blood sugar control.
Uses / Indications
-
Type 2 diabetes mellitus: For persistent hyperglycemia in adults when diet, exercise, or lower-strength medicines are insufficient.
-
Prevents diabetes complications: Regular use helps protect against kidney, eye, nerve, heart, and vascular damage caused by poorly controlled diabetes.
How it Works / Key Benefits
-
Glimepiride: Stimulates pancreatic insulin release, improves glucose uptake, and lowers postprandial blood sugar.
-
Metformin (PR): Reduces liver glucose production, delays intestinal glucose absorption, increases peripheral insulin sensitivity; prolonged release ensures steady effect with reduced GI side effects.
-
The bilayered tablet provides synergistic glucose control, lowering HbA1c more effectively than either agent alone.
Dosage & Administration
-
Usually one tablet daily with the first major meal (preferably breakfast); exact dose, duration, and timing are determined by the physician.
-
Swallow whole with water; do not chew, crush, or break.
-
Take at the same time daily, maintain regular meals, and monitor blood sugar routinely.
-
Do not double dose if missed; continue scheduled dosing.
Safety & Side Effects
-
Common: Low blood sugar (hypoglycemia), mild GI upset (nausea, diarrhea), taste disturbance, weight changes, headache.
-
Serious/rare: Lactic acidosis with metformin (seek urgent care for rapid breathing, vomiting), allergic reactions, anemia, liver/kidney dysfunction.
-
Not for type 1 diabetes, diabetic ketoacidosis, severe kidney/liver impairment, or in metabolic acidosis.
-
Alcohol and some medicines increase risk of adverse effects—avoid without medical advice.
-
Regular monitoring of blood, kidney, and liver function is recommended during use.
Note:
DAILYGLIM M1 FORTE is for long-term diabetes control. Continue a healthy lifestyle and physician follow-up for best results and safety.







Leave a Reply